covid
Buscar en
Revista Brasileira de Cardiologia Invasiva (English Edition)
Toda la web
Inicio Revista Brasileira de Cardiologia Invasiva (English Edition) Efficacy of Drug-Eluting Balloon in the Treatment of Ostial Left Anterior Descen...
Información de la revista
Vol. 22. Núm. 2.
Páginas 183-187 (junio 2014)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 22. Núm. 2.
Páginas 183-187 (junio 2014)
Case Report
Open Access
Efficacy of Drug-Eluting Balloon in the Treatment of Ostial Left Anterior Descending Artery In-Stent Restenosis
Visitas
1966
Guy Fernando de Almeida Prado Jr.
Autor para correspondencia
gfaprado@gmail.com

Correspondence to: Guy Fernando de Almeida Prado Jr. Setor de Hemodinâmica do Instituto do Coração – Avenida Dr. Enéas de Carvalho Aguiar, 44 – Cerqueira César – CEP: 05403-900 – São Paulo, SP, Brazil
, Cristiano Guedes Bezerral, Gustavo Martins Pereira Alves, Marcio Augusto Meirelles Truffa, Expedito Eustaquio Ribeiro da Silva, Pedro Alves Lemos Neto
Instituto do Coração, Hospital das Clínicas, School of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil.
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
ABSTRACT

Percutaneous coronary intervention with drug-eluting balloons has emerged as an adjunctive strategy in the setting of Interventional Cardiology. When compared to drug-eluting stents, drug-eluting balloons offer advantages such as immediate and homogeneous drug release in the arterial wall, absence of polymers that can induce chronic inflammatory reactions, and the potential for using dual antiplatelet therapy for a shorter period of time. Furthermore, in some situations, additional stenting is not desirable, which turns this modality into an interesting option. We report the case of a patient with acute coronary syndrome in whom this intervention was chosen to treat an ostial left anterior descending artery in-stent restenosis.

DESCRIPTORS: Coronary restenosis. Percutaneous coronary intervention. Angioplasty, balloon. Paclitaxel.

RESUMO

Eficácia do Balao Farmacológico no Tratamento de Reestenose Intra-Stent em Óstio da Arteria Descendente Anterior

A intervengao coronariana percutanea com balao farmacológico surgiu como estrategia adjunta no cenário da Cardiologia Intervencionista. Em comparagao com o stent farmacológico, o balao farmacológico oferece vantagens, como a liberagao imediata e homogénea do fármaco na parede arterial, a ausencia de polímeros que podem induzir a reagoes inflamatórias crónicas e o potencial de utilizar a dupla anti-agregagao plaquetária por menor tempo. Além disso, em algumas situagoes, nao sao desejáveis implantes adicionais de stents, o que torna essa modalidade uma opgao interessante. Relatamos aqui o caso de uma paciente em síndrome coronariana aguda, em que foi feita a opgao por esse tipo de intervengao em uma reestenose de stent nao farmacológico em óstio de arteria descendente anterior.

DESCRITORES: Reestenose coronária. Intervengao coronária percutanea. Angioplastia com balao. Paclitaxel.

El Texto completo está disponible en PDF
REFERENCES
[1.]
B. Scheller, C. Hehrlein, W. Bocksch, W. Rutsch, D. Haghi, U. Dietz, et al.
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.
N Engl J Med, 355 (2006), pp. 13-24
[2.]
C.W. Hwang, D. Wu, E.R. Edelman.
Physiological transport forces govern drug distribution for stent-based delivery.
Circulation, 104 (2001), pp. 600-605
[3.]
B. Scheller, U. Speck, M. Bohm.
Prevention of restenosis: is angioplasty the answer?.
Heart, 93 (2007), pp. 539-541
[4.]
K. Bonaventura, S. Sonntag, F.X. Kleber.
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
Eurointervention, 7 (2011), pp. K106-K111
[5.]
D.G. Mathey, I. Wendig, M. Boxberger, K. Bonaventura, F.X. Kleber.
Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial.
Eurointervention, 7 (2011), pp. K61-K65
[6.]
M. Werk, S. Langner, B. Reinkensmeier, H.F. Boettcher, G. Tepe, U. Dietz, et al.
Inhibition of restenosis in femoralpopliteal arteries: plactaxel-coated versus uncoated balloon: femoral plactaxel randomized pilot trial. Circulation.
Circulation, 118 (2008), pp. 1358-1365
[7.]
F. Roques, S.A. Nashef, P. Michel, E. Gauducheau, C. de Vincentiis, E. Baudet, et al.
Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients.
Eur J Cardiothorac Surg, 15 (1999), pp. 816-822
[8.]
B. Scheller, U. Speck, C. Abramjuk, U. Bernhardt, M. Böhm, G. Nickenig.
Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.
Circulation, 110 (2004), pp. 810-814
[9.]
B. Cremers, U. Speck, N. Kaufels, D. Mahnkopf, M. Kühler, M. Böhm, et al.
Drug-eluting balloon: very short-term exposure and overlapping.
Thromb Haemost, 101 (2009), pp. 201-206
[10.]
B. Scheller, C. Hehrlein, W. Bocksch, W. Rutsch, D. Haghi, U. Dietz, et al.
Two year follow-up after treatment of coronary in-stent restenosis with a pacl itaxel-coated balloon catheter.
Clin Res Cardiol, 97 (2008), pp. 773-781
[11.]
M. Unverdorben, C. Vallbracht, B. Cremers, H. Heuer, C. Hengstenberg, C. Maikowski, et al.
Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis.
Circulation, 119 (2009), pp. 2986-2994
[12.]
W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, et al.
Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization.
Eur Heart J, 31 (2010), pp. 2501-2555
[13.]
F. Alfonso, M.J. Pérez-Vizcayno, A. Cárdenas, B. García Del Blanco, B. Seidelberger, A. Iñiguez, et al.
A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
J Am Coll Cardiol, 63 (2014), pp. 1378-1386
[14.]
H. Rittger, J. Brachmann, A.M. Sinha, M. Waliszewski, M. Ohlow, A. Brugger, et al.
A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study.
J Am Coll Cardiol, 59 (2012), pp. 1377-1382
[15.]
R.A. Byrne, F.J. Neumann, J. Mehilli, S. Pinieck, B. Wolff, K. Tiroch, et al.
Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial.
[16.]
S. Habara, M. Iwabuchi, N. Inoue, S. Nakamura, R. Asano, S. Nanto, et al.
A multicenter randomized comparison of paclitaxel- coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
Am Heart J, 166 (2013), pp. 527-533
Copyright © 2014. Sociedade Brasileira de Hemodinâmica e Cardiologia Invasiva
Descargar PDF
Opciones de artículo